Boehringer Ingelheim begins trials for ‘Viagra for women’

Share this article:
Boehringer Ingelheim has begun trials on a sex drug that has been dubbed a “Viagra for women,” because it works directly on the pleasure zones of the female brain to restore low libido. The drug, known as flibanserin, was originally tested as an anti-depressant. Participants in those trials reported that while their depression was no better, they had experienced a boost in sexual desire. Boehringer is reportedly conducting four trials on 5,000 women in 220 locations and is hoping to receive approval from the FDA in 2009. Boehringer’s medical director for the UK, Dr. Charles de Wet, told the British newspaper The Times that “no excessive sexual side effects have been reported from the treatment in any clinical trial.” Flibanserin takes several weeks for a significant effect to build up in the brain, meaning that, unlike Viagra, it cannot be “popped” in advance of an evening out.
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.